ArticleNature communications2026
A non-enzymatic function of neuraminidase 1 restrains hepatic glucagon response in mice.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Dysregulated hepatic gluconeogenesis driven by glucagon is a key contributor to hyperglycemia in diabetes, yet the molecular mechanisms that restrain this pathway remain incompletely understood. This study reveals neuraminidase 1 (NEU1) as a suppressor of hepatic glucagon-driven gluconeogenesis in diabetes. We found that glucagon challenge downregulates hepatic NEU1 expression, inversely correlating with fasting blood glucose levels in individuals with diabetes. Functionally, liver-specific NEU1 overexpression antagonizes hepatic gluconeogenesis in glucagon-challenged mice and high fat diet (HFD)-fed mice, while NEU1 knockout augments glucagon response. Additionally, NEU1 inhibits hepatic gluconeogenesis in a non-enzymatic manner. Mechanistically, NEU1 interacts with SAM68 to activate GCN5 promoter, leading to increase of PGC-1α acetylation. The inhibitory effect of NEU1 overexpression on gluconeogenesis is abrogated by GCN5 knockdown in HFD-fed mice. A NEU1-targeted screening strategy identified α-hederin and oleanolic acid as synergistic inhibitors of hepatic glucagon response through NEU1 stabilization and SAM68 binding enhancement. Here we show an inhibitory role of NEU1 in the hepatic glucagon response and suggest a potential avenue for targeting NEU1 to treat diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.